RXII vs. BLRX, CNTB, SLS, THTX, MNOV, VTVT, PRPH, HOOK, CELU, and TCRT
Should you be buying RXi Pharmaceuticals stock or one of its competitors? The main competitors of RXi Pharmaceuticals include BioLineRx (BLRX), Connect Biopharma (CNTB), SELLAS Life Sciences Group (SLS), Theratechnologies (THTX), MediciNova (MNOV), vTv Therapeutics (VTVT), ProPhase Labs (PRPH), Hookipa Pharma (HOOK), Celularity (CELU), and Alaunos Therapeutics (TCRT). These companies are all part of the "medical" sector.
RXi Pharmaceuticals (NASDAQ:RXII) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.
RXi Pharmaceuticals has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500.
BioLineRx received 312 more outperform votes than RXi Pharmaceuticals when rated by MarketBeat users. Likewise, 73.26% of users gave BioLineRx an outperform vote while only 68.09% of users gave RXi Pharmaceuticals an outperform vote.
RXi Pharmaceuticals has higher earnings, but lower revenue than BioLineRx. BioLineRx is trading at a lower price-to-earnings ratio than RXi Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
BioLineRx has a consensus target price of $21.00, indicating a potential upside of 2,388.15%. Given BioLineRx's higher possible upside, analysts plainly believe BioLineRx is more favorable than RXi Pharmaceuticals.
BioLineRx has a net margin of 0.00% compared to RXi Pharmaceuticals' net margin of -4,990.20%. BioLineRx's return on equity of -325.10% beat RXi Pharmaceuticals' return on equity.
In the previous week, BioLineRx had 4 more articles in the media than RXi Pharmaceuticals. MarketBeat recorded 4 mentions for BioLineRx and 0 mentions for RXi Pharmaceuticals. BioLineRx's average media sentiment score of 1.19 beat RXi Pharmaceuticals' score of 0.00 indicating that BioLineRx is being referred to more favorably in the news media.
9.6% of RXi Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.6% of BioLineRx shares are owned by institutional investors. 1.0% of RXi Pharmaceuticals shares are owned by company insiders. Comparatively, 1.1% of BioLineRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
BioLineRx beats RXi Pharmaceuticals on 12 of the 17 factors compared between the two stocks.
Get RXi Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for RXII and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RXII and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RXi Pharmaceuticals Competitors List
Related Companies and Tools
